This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-11. Anything still debated is marked as such rather than presented as settled.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
palatal partial thickness flap palatal full-partial thickness flap tuberosity partial thickness flap Contrary to the donor site for a free gingival graft, the surgeon is able to achieve primary closure at the donor site for a SECT. Langer later described the SECT as a method by which to augment concavities and irregularities of the alveolar ridge following traumatic extractions, advanced periodontitis or developmental defects. Currently, though, such augmentation of hard tissue defects tends to be done with hard tissue replacements, namely bone graft materials. However, it was only in 1985 that Langer proposed the SECT for root coverage following gingival recession.
=== Cystatin C === Problems with creatinine (varying muscle mass, recent meat ingestion (much less dependent on the diet than urea), etc.) have led to evaluation of alternative agents for estimation of GFR. One of these is cystatin C, a ubiquitous protein secreted by most cells in the body (it is an inhibitor of cysteine protease). Cystatin C is freely filtered at the glomerulus. After filtration, Cystatin C is reabsorbed and catabolized by the tubular epithelial cells, with only small amounts excreted in the urine. Cystatin C levels are therefore measured not in the urine, but in the bloodstream. Equations have been developed linking estimated GFR to serum cystatin C levels. Most recently, some proposed equations have combined sex, age, adjusted cystatin C and creatinine. In 2022, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN)'s Joint Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases recommended national efforts to facilitate increased, routine, and timely use of cystatin C. They noted that cystatin C would be useful particularly to confirm estimated GFR in adults who are at risk for or have chronic kidney disease. They suggested that combining filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone.
BASF is an acronym for Badische Anilin- und Sodafabrik (German for 'Baden Aniline and Soda Factory'). It was founded by Friedrich Engelhorn on 6 April 1865 in Mannheim, in the German-speaking state of Baden. Engelhorn had been responsible for setting up a gasworks and street lighting for the town council in 1861. The gasworks produced tar as a by-product from coal, and Engelhorn used this to extract aniline for the production of dyes. BASF was set up in 1865, to produce other chemicals necessary for dye production, notably soda and acids. The plant, however, was erected on the other side of the Rhine river at Ludwigshafen because the town council of Mannheim was afraid that the air pollution from the chemical plant could bother the inhabitants of the town. In 1866, the dye production processes were also moved to the BASF site.
Rennie's 1833 supplement to the pharmacopeias admitted its use as an "expectorant, diuretic, and emmenagogue" in doses of 10 grains to 1 scruple (0.6–1.3g) of the powdered dried herb, but dismissed the use of the Pennyroyal Water (Aqua Pulegii) as "popularly but erroneously supposed" to be an abortifacient [no mention is made of toxicity]. Chemicals in the pennyroyal plant cause the uterine lining to contract, causing a woman's uterine lining to shed. Since the U.S. Congress passed the Dietary Supplement Health and Education Act in October 1994, all manufactured forms of pennyroyal in the United States have carried a warning label against its use by pregnant women, but pennyroyal is not regulated by the U.S. Food and Drug Administration. At least one study has shown pennyroyal oil to have potent acaricidal activity against house dust mites.
Tryptamines: N-methyltryptamine (NMT) (isomer of AMT) and methylisopropyltryptamine (MiPT) (isomer of DET) Methoxytryptamines: 4-MeO-DMT (isomer of 5-MeO-DMT) and 5-MeO-DPT (isomer of 5-MeO-DiPT) Hydroxytryptamines: 6-HO-DMT and 7-HO-DMT (both isomers of psilocin (4-HO-DMT)) Phenethylamines: Scalines: escaline (isomer of TMA) 2Cs: 2C-G (isomer of 2C-E and DOM) Amphetamines: DOx TMA-2 (2,4,5-TMA) (isomer of TMA), Aleph-2 (isomer of 2C-T-4), and Aleph-4 (isomer of 2C-T-7) 4Cs: Ariadne (isomer of DOET) MDxx: MBDB (isomer of MDEA Others: TMA-6 (2,4,6-TMA) (isomer of TMA) Others have not been explicitly noted by the United States DEA but may also be considered. Examples include the DET isomers MPT and MiPT and the LSD isomers MiPLA and LAMPA, among others.
Sources: en.wikipedia.org
H2O2 + R'H2 → R' + 2 H2O thus eliminating the poisonous hydrogen peroxide in the process. This reaction is important in liver and kidney cells, where the peroxisomes neutralize various toxic substances that enter the blood. Some of the ethanol humans drink is oxidized to acetaldehyde in this way. In addition, when excess H2O2 accumulates in the cell, catalase converts it to H2O through this reaction:
Chinese officials described these criticisms as an attempt to politicise the study. Scientists involved in the WHO report, including Liang Wannian, John Watson, and Peter Daszak, objected to the criticism, and said that the report was an example of the collaboration and dialogue required to successfully continue investigations into the matter. In a letter published in Science, a number of scientists, including Ralph Baric, argued that the accidental laboratory leak hypothesis had not been sufficiently investigated and remained possible, calling for greater clarity and additional data. Their letter was criticized by some virologists and public health experts, who said that a "hostile" and "divisive" focus on the WIV was unsupported by evidence, and would cause Chinese scientists and authorities to share less, rather than more data.
== Background == This was the first of the new President Trump's executive orders and was a mass undoing of the previous president's policies on a wide range of issues. Its core effect was the rescinding of several executive orders ordered by President Biden. It was followed that day by 25 other executive orders covering a wide range of policies and was signed in an open to the public event with attendance by Vice President JD Vance.
==== TP0624 ==== Outer Membrane Protein A (OmpA) domain-containing proteins are necessary for maintaining structural integrity in gram-negative bacteria. These domains contain peptidoglycan binding sites which creates a "structural bridge between the peptidoglycan layer and the outer memebrane." The protein TP0624 found in T. pallidum has been proposed to facilitate this structural link, as well as interactions between outer membrane proteins and corresponding domains on the thin peptidoglycan layer.
Sources: en.wikipedia.org
== History == The British have had a system of heroin maintenance since the 1920s. For decades it supplied a few hundred addicts nationwide, most of whom were doctors themselves. It was de-emphasized considerably during the 1960s-1980s as a result of the U.S.-led war on drugs. In the 1980s and early 1990s, Dr John Marks ran heroin-prescribing clinics in Liverpool, Widnes and Warrington that were highly controversial. Because of the lack of large-scale trials, only anecdotal evidence existed as to the efficacy of the treatment. This changed in 1994 when Switzerland, faced with one of the largest open drug scenes in Europe at the time, started large-scale trials on the potential use of diamorphine as a maintenance drug. They proved diamorphine to be a viable maintenance drug which has shown equal or better rates of success than methadone in terms of assisting long-term users establish stable, crime-free lives. These results encouraged countries like Germany and the Netherlands to conduct their own trials and finally to include heroin-assisted treatment fully as a part of the national health system in 2009. In Switzerland, heroin has been made available under supervision to addicts since around 1994. Several studies have been conducted between 1994 and 1996.
King Pellam, wounded by Balin (as in the Post-Vulgate). In the Vulgate's clearer Grail lineage, Pelles is the son of Pellehan and is wounded in a separate accident, while in the Post-Vulgate Pelles and Pellehan are brothers. The further step of mistaking them as the same character is understandable; Malory confuses the brothers Ywain and Ywain the Bastard, whom he eventually regards as the same character, after treating them as separate. King Pelles, grandfather of Galahad, described as "the maimed king". In one passage, he is explicitly identified with Pellam; in another, he is said to have suffered his wound under different circumstances. King Pescheour (or Petchere), lord of the Grail Castle, who never appears (at least, not under that name). He owes his existence to a mistake by Malory, who took the Old French roy peschour ("Fisher King", a phrase that Malory never otherwise uses) for a name rather than an epithet. Nevertheless, Malory treats him as distinct from Pelles. An anonymous, bedridden Maimed King, healed by Galahad at the climax of the Grail Quest. He is distinct from Pelles, who has just been sent out of the room, and who is, anyway, at least mobile. In addition, there is King Pellinore, Perceval's father (in other versions of the legend, Perceval is related to the Grail Kings line). It appears that Malory intended to have one Maimed King who was wounded by Balin and suffered until healed by his grandson Galahad, but he never successfully reconciled his sources.
Prince Harry becomes the first senior member of the British royal family to give evidence in a court case in more than 130 years when he appears at the High Court to give evidence in his case against Mirror Group Newspapers. The Advertising Standards Authority bans a 2022 campaign by Shell plc for being "likely to mislead" consumers. 7 June Figures produced by Halifax Bank indicate house prices have dropped by 1% compared to 2022, the first such fall since 2012. It is announced that The Daily Telegraph and Sunday Telegraph, as well as The Spectator, are to be put up for sale to recover debts incurred by the publications' parent company. 8 June Prime Minister Rishi Sunak holds a joint press conference with US president Joe Biden at the White House to announce the Atlantic Declaration, an agreement to strengthen economic ties between the UK and US. Caroline Lucas, the Green Party's former leader and only MP, announces that she is stepping down from Parliament at the next election. 9 June The UK government announces that the planned windfall tax on oil and gas companies will be suspended if prices return to normal levels for a sustained period. Nadine Dorries announces she will stand down as Conservative MP for Mid Bedfordshire with immediate effect, triggering a by-election. On 14 June 2023 she said that she had submitted a subject access request to the House of Lords Appointments Commission (HOLAC) and was waiting to resign until she had received all unredacted "WhatsApps, text messages, all emails and minutes of meetings" related to why she was denied a peerage.
=== Interaction proteomics and protein networks === Interaction proteomics is the analysis of protein interactions from scales of binary interactions to proteome- or network-wide. Most proteins function via protein–protein interactions, and one goal of interaction proteomics is to identify binary protein interactions, protein complexes, and interactomes. Several methods are available to probe protein–protein interactions. While the most traditional method is yeast two-hybrid analysis, a powerful emerging method is affinity purification followed by protein mass spectrometry using tagged protein baits. Other methods include surface plasmon resonance (SPR), protein microarrays, dual polarisation interferometry, microscale thermophoresis, kinetic exclusion assay, and experimental methods such as phage display and in silico computational methods. Knowledge of protein-protein interactions is especially useful in regard to biological networks and systems biology, for example in cell signaling cascades and gene regulatory networks (GRNs, where knowledge of protein-DNA interactions is also informative). Proteome-wide analysis of protein interactions, and integration of these interaction patterns into larger biological networks, is crucial towards understanding systems-level biology.
== External links == Laws, ordinances, guidelines, expert opinions and publications on radiation protection Archived 2018-03-18 at the Wayback Machine, timeline since 2002 of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection. Retrieved on November 28, 2017. Guidelines for quality assurance in radiology Archived 2013-07-15 at the Wayback Machine (PDF) German Medical Association, November 23, 2007. Retrieved December 4, 2017. DIN Radiology Standards Archived 2013-07-15 at the Wayback Machine (PDF) DIN Radiology Standards Committee NAR in cooperation with the German Radiological Society, June 2015, accessed December 4, 2017. Radiation protection in veterinary medicine - Guideline to the Radiation Protection Ordinance (StrlSchV) and the X-ray Ordinance (RöV) (PDF) September 25, 2014, Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety, Division Medical-Biological Affairs of Radiation Protection Ref. RS II 4 - 11432/7. Retrieved November 28, 2017. Radioactivity and radiation protection (PDF; 6.6 MB) Federal Office of Public Health (Switzerland), July 2007, accessed November 25, 2017. Overview of international radiation protection associations and organizations, Austrian Association for Radiation Protection. Retrieved December 3, 2017. Human Radiation Experiments DOE Openness. Retrieved January 10, 2018. Department of Energy OpenNet Resources. Retrieved January 10, 2018. Igor Gusev, Angelina Guskova, Fred A. Mettler: Medical Management of Radiation Accidents, Second Edition.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.